Our following validation using alternative HDAC3-specific targeting compounds, a pan-HDACi, and multiple sgRNAs as well as both human and mouse lymphoma cell lines further confirmed the on-target effects and general applicability. This evidence concerns the gene HDAC3 and lymphoma.